Urinary phthalate metabolite concentrations are negatively associated with follicular fluid anti-müllerian hormone concentrations in women undergoing fertility treatment

Caitlin R. Sacha\textsuperscript{a,b,c,*}, Irene Souter\textsuperscript{a,c}, Paige L. Williams\textsuperscript{d}, Jorge E. Chavarro\textsuperscript{d,e,f}, Jennifer Ford\textsuperscript{d}, Shruthi Mahalingaiah\textsuperscript{a,c,d}, Patricia K. Donahoe\textsuperscript{b,c}, Russ Hauser\textsuperscript{d}, David Pépin\textsuperscript{b,c}, Lidia Mínguez-Alarcón\textsuperscript{d,f}

\textsuperscript{a}Massachusetts General Hospital Fertility Center, Boston, MA, United States
\textsuperscript{b}Massachusetts General Hospital Pediatric Surgical Research Laboratories, Boston, MA, United States
\textsuperscript{c}Harvard Medical School, Boston, MA, United States
\textsuperscript{d}Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA, United States
\textsuperscript{e}Department of Nutrition and Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, United States
\textsuperscript{f}Channing Division of Network Medicine, Harvard Medical School & Brigham and Women’s Hospital, United States

Abstract

Exposure to phthalates, endocrine-disrupting chemicals commonly used as plasticizers and in consumer products, has been associated with infertility and premature ovarian failure. Our objective was to investigate whether urinary phthalate metabolite concentrations were associated with pre-ovulatory follicular fluid (FF) anti-müllerian hormone (AMH) concentrations in women undergoing fertility treatment. This cross-sectional analysis included 138 women with urinary phthalate data available in the Environment and Reproductive Health (EARTH) Study (2010–2016) in whom FF AMH concentrations were quantified using a sandwich enzyme-linked...
immunosorbent assay (ELISA). We also quantified 8 phthalate metabolite concentrations using tandem mass spectrometry in 1–2 urine samples per cycle (total 331 urines) and calculated the cycle-specific geometric mean for each metabolite. We applied cluster-weighted generalized estimating equation models (CWGEE) to evaluate the associations of tertiles of urinary phthalate metabolite concentrations with log-transformed FF AMH concentrations adjusting for potential confounders. Study participants had median age of 34.0 years (IQR 32.0, 37.0), 83% were white, and median BMI of 23.1 kg/m\(^2\) (IQR 21.2, 26.1). The following stimulation protocols were used: luteal phase agonist (70%), antagonist (14%), or flare (16%). Urinary concentrations of select phthalate metabolites were negatively associated with FF AMH. For example, women whose urinary mEOHP was in the lowest tertile (range 0.30–4.04 ng/ml) had an adjusted mean FF AMH of 0.72 ng/mL (95% CI = 0.36, 1.44), compared to women in the highest tertile (range 9.90–235), who had an adjusted mean of 0.24 ng/mL (95% CI = 0.12–0.48, p < 0.05). The negative association between urinary concentrations of certain phthalate metabolites with FF AMH concentrations may have implications for antral follicle recruitment and fertility treatment outcomes.

Keywords
IVF; Follicular fluid; AMH; Phthalates

1. Introduction

Phthalates are endocrine disrupting chemicals that are ubiquitous in some plastics and everyday consumer products, such as detergents, medical devices, and food packaging materials (Begum et al., 2020; Hauser and Calafat, 2005; Katsikantami et al., 2016). Phthalates easily leach from plastic products into the environment, leading to daily human exposure. After exposure, high molecular weight phthalates such as di-(2-ethylhexyl) phthalate (DEHP) are rapidly metabolized to hydrolytic monoesters, such as mono-(2-ethylhexyl) phthalate (MEHP), which in turn form oxidative metabolites after enzymatic oxidation of their alkyl chain (Hauser and Calafat, 2005). Four phthalates (DEHP, dibutyl phthalate, benzyl butyl phthalate, di-isobutyl phthalate) are subjects of Annex XVII of Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) Regulation in Europe (Commission Regulation, 2018).

Phthalates have been associated with female reproductive toxicity in animal studies due in large part to their endocrine disrupting properties (Hauser and Calafat, 2005). For example, exposure to DEHP and MEHP has a negative effect on murine reproduction via accelerated primordial follicle recruitment, increased follicular atresia, cell cycle dysregulation, and altered steroidogenesis (Hannon et al., 2015; Craig et al., 2014; Gupta et al., 2010; Wang et al., 2012; Hannon et al., 2015). Many phthalates are considered endocrine-disrupting chemicals (EDCs) in humans as well (Green et al., 2021; Heindel et al., 2017). Human exposure can be quantified by detection of phthalates metabolites in urine (Silva et al., 2004; Silva et al., 2007). Prior epidemiological studies, including those by our group, have demonstrated that maternal urinary phthalate concentrations are inversely associated with ovarian reserve, as assessed by antral follicle count (Messerlian et al., 2016); and also with...
in vitro fertilization (IVF) outcomes, specifically oocyte yield, oocyte fertilization, embryo quality, clinical pregnancy, and live birth (Hauser et al., 2016; Mínguez-Alarcón et al., 2019; Begum et al., 2021; Machtinger et al., 2018).

Anti-Müllerian hormone (AMH), also known as Müllerian inhibiting substance (MIS), produced by the granulosa cells of preantral and early antral follicles (Weenen, 2004), is a reliable marker of ovarian reserve and response to gonadotropin medications (Buyuk et al., 2011). We recently reported that AMH in the pre-ovulatory follicular fluid (FF) of women undergoing IVF was positively associated with the probability of clinical pregnancy, even after adjusting for important confounders such as age and stimulation protocol (Sacha et al., 2020). Other studies have also observed positive associations between FF AMH and outcomes such as fertilization rate, embryo quality, and implantation rate (Fanchin et al., 2007; Kim et al., 2014). Therefore, FF AMH, while reflecting other measures of ovarian reserve such as serum AMH, is an indicator of granulosa cell function and plays an important physiologic role in oocyte development in the follicle. Exposure to DEHP and mono-(2-ethylhexyl) phthalate (MEHP) (Gupta et al., 2010; Davis et al., 1994) was shown to reduce estradiol production by granulosa cells of antral follicles, which led us to hypothesize that AMH production could also be reduced due to granulosa cell toxicity. Examining FF AMH is thus crucial to understand the mechanisms by which phthalate exposure effects the local ovarian environment and folliculogenesis.

In this study, we evaluated whether maternal urinary phthalate metabolite concentrations were associated with pre-ovulatory FF AMH concentrations. We hypothesized that urinary phthalate metabolites would be negatively associated with FF AMH concentrations.

2. Materials and methods

2.1. Study design

Participants included in this analysis were women seeking fertility care at the Massachusetts General Hospital (MGH) Fertility Center, a single academic fertility center in Boston, Massachusetts, who enrolled in the Environment and Reproductive Health (EARTH) Study (2004–2019). The EARTH Study was a prospective cohort study that aimed to investigate environmental and dietary factors in relation to fertility and reproductive health (Mínguez-Alarcón et al., 2016). Women between the ages of 18 and 45 years old with any infertility diagnosis were eligible to enroll. The MGH Fertility Center additionally has a maximum body mass index (BMI) threshold of 40 kg/m² to undergo treatment. FF AMH concentrations were quantified from 162 women contributing 217 IVF cycles in which at least two FF samples were collected (between 2010 and 2016). Of those, 138 women who underwent 179 fresh IVF cycles had urinary phthalate metabolite concentration available and are included in the present cross-sectional analysis, since both urine and FF samples were collected the same day. We have previously shown that women in the EARTH study with FF AMH concentrations measured had similar demographic and reproductive characteristics compared to women who did not (Sacha et al., 2020). Participants signed an informed consent prior to study enrollment. The EARTH Study is approved by the institutional review boards at MGH (Partners IRB #1999P008167) and Harvard T.H. Chan School of Public Health.
2.2. Ovarian stimulation protocols

All study participants underwent a standard infertility work-up as previously described (Messerlian et al., 2018; Souter et al., 2013). Infertility diagnosis was assigned according to previously described definitions of the Society for Assisted Reproductive Technology (SART) (SART, 2015). SART diagnoses include: 1) male factor infertility; 2) female factor infertility which included endometriosis, diminished ovarian reserve, tubal or ovulatory disorders, or other causes; and 3) unexplained infertility (idiopathic).

Patients then underwent controlled ovarian hyperstimulation by luteal-phase gonadotropin-releasing hormone (GnRH) agonist, GnRH-antagonist downregulation, or GnRH agonist flare protocol, with follicular synchronization and pituitary down-regulation as clinically indicated and previously described (Souter et al., 2012; Gaskins et al., 2019; Sacha et al., 2019). During treatment with recombinant gonadotropins (follitropin beta, Follistim, Merck, Kenilworth, NJ, or follitropin alpha, Gonal-F, EMD-Serono; and menotropins, Menopur or Repronex, Ferring Pharmaceuticals, Parsippany, NJ), patients were serially monitored with transvaginal ultrasound and serum estradiol (E$_2$) to assess follicular measurements and endometrial thickness. Once at least three follicles reached 16 mm or more in diameter and the E$_2$ level was > 600 pg/mL, intramuscular human chorionic gonadotropin (hCG) (10,000 IU, Novarel, Ferring Pharmaceuticals or 10,000 IU, Pregnyl, Merck) was administered to induce final oocyte maturation. The peak serum E$_2$ concentration was defined as the highest level of E$_2$ preceding the oocyte retrieval and obtained on the day of hCG administration. The patients underwent a transvaginal ultrasound-guided oocyte retrieval 35–37 h later (Chavarro et al., 2012). Intramuscular progesterone, 50 mg per day, was begun on the day after oocyte retrieval and continued until 10 weeks gestation if the patient conceived.

2.3. FF collection and AMH quantification

FF was collected as previously described from the first three (N = 102 women, 74%) or two (N = 36 women, 26%) dominant (>16 mm) follicles punctured during each patient’s egg retrieval (Sacha et al., 2020). The fluid from each follicle was separately aspirated into a tube with 1 ml sterile culture media so that FF volume could be accurately calculated. After identification and transfer of the oocytes by the embryologist, the FF from each follicle was transferred to a 15 ml tube and the collection time and sample volumes logged. The FF was then centrifuged at 3000 rpm for 10 min to remove material such as red blood cells and granulosa cells, and the supernatant was stored in aliquots at − 80C, taking care not to pool FF from different follicles.

AMH concentration was quantified in FF of the study patients using a sandwich enzyme-linked immunosorbent assay (ELISA) with mouse monoclonal anti-human recombinant antibody (6E11), which binds to the AMH homodimer, as the primary antibody, and rabbit polyclonal anti-AMH antibody (MGH6), as the secondary antibody (Sacha et al., 2020; Kano et al., 2017; Hudson et al., 1990). The standard curve was created using recombinant AMH protein “LRMIS” (created from AMH/MIS cDNA with human albumin leader sequence (L) and modified cleavage site (R)) in blocking buffer (1% BSA/PBS and Tween 20 (PBST)), which has been proposed as an international standard by the World Health
Organization (WHO) (Pepin et al., 2013; Ferguson et al., 2018). This ELISA produces absolute AMH concentrations that strongly correlate with the Gen II Elisa commercial assay used by the MGH clinical laboratories during the study time period (Spearman $r^2 = 0.81$, evaluated for a subset of 22 women with serum AMH concentrations previously performed for their fertility work up (Sacha et al., 2020). Intra-assay variability was 12.0% and inter-assay variability was 15.5% with an assay limit of detection (LOD) of 0.034–0.068 ng/mL based on the standard curve values. Values below the levels represent extrapolation from the standard curve. Prior to analysis, FF AMH concentration was corrected for sample culture media volume using the formula: corrected AMH concentration = (measured AMH concentration * measured volume)/(measured volume – 1 ml).

2.4. Urine collection and phthalate metabolite quantification

Women provided one (23%) or two (77%) spot urine samples per IVF cycle, with the first one collected between days 3 and 9 of the follicular phase (not necessarily a fasting sample), and the second one collected as a fasting sample in the morning prior to the oocyte retrieval, approximately one week apart. Urine was collected in a sterile polypropylene specimen cup. Specific gravity (SG), used as a covariate in the models to account for urine dilution, was measured at room temperature using a handheld refractometer (National Instrument Company, Inc., Baltimore, MD, USA) calibrated with deionized water before each measurement. The urine was divided into aliquots, frozen, and stored at – 80 °C. Urine samples were shipped on dry ice overnight to the Center for Disease Control (CDC) where they were stored at or below – 40 °C until analysis. The CDC laboratory is certified by the Health Care Financing Administration to comply with the requirements set forth in the Clinical Laboratory Improvement Amendments of 1988 (CLIA ’88).

All analytical measurements follow strict quality control/quality assurance according to CLIA guidelines. For example, along with study samples, each analytical run includes a set of calibrators, reagent blanks, and high- and low-concentration quality control (QC) materials. Concentrations of the QCs were evaluated using standard statistical probability rules (Caudill et al., 2008).

As previously described (Hauser et al., 2016); we used online solid-phase extraction coupled with isotope dilution-high-performance liquid chromatography-tandem mass spectrometry to quantify the urinary concentrations of phthalate metabolites, including monoethyl phthalate (MEP); mono-n-butyl phthalate (MBP); monoisobutyl phthalate (MiBP); monobenzyl phthalate (MBzP); MEHP; mono(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP); mono(2-ethyl-5-oxohexyl) phthalate (MEOHP); and mono(2-ethyl-5-carboxypentyl) phthalate (MECPP) (Silva et al., 2007). LOD ranged from 0.1 to 1.2 ng/mL. Concentrations below the LOD were assigned a value equal to the LOD divided by the square root of 2. The geometric mean of the phthalate metabolite concentrations from two spot urine samples collected during each IVF cycle was used as a measure of cycle-specific urinary biomarker concentration, except for cycles with only one urine sample for which the single biomarker concentration was used as the cycle-specific urinary biomarker concentration. A similar approach was used to calculate the cycle-specific SG. Because of the potential for bias, rather than correcting by SG using a formula, we adjusted for SG by including this as a covariate in the statistical models (Schisterman et al., 2005; Barr et al., 2005).
calculated the molar sum of DEHP metabolites (∑DEHP) by dividing each DEHP metabolite concentration by its molecular weight (g/mol) and then summing: ([MEHP × (1/278.34)] + [MEHHP × (1/294.34)] + [MEOHP × (1/292.33)] + [MECPP × (1/308.33)]). Similarly, we calculated the molar sum of non-DEHP metabolites (∑non-DEHP) by dividing each non-DEHP metabolite concentration by its molecular weight and then summing: ([MEP × (1/194.18)] + [MBP × (1/222.24)] + [MiBP × (1/222.24)] + [MBzP × (1/256.25)]).

### 2.5. Statistical analyses

We present demographic and reproductive characteristics of the study participants using median ± interquartile ranges (IQRs) or counts (%), and distribution of urinary concentrations of phthalate metabolites using percentiles and geometric means ± standard deviations (SDs). Mean intra-cycle FF AMH concentrations were calculated as the sum of FF AMH concentrations in the two or three selected follicles, divided per cycle by the number of follicles. Due to right skewness, we log-transformed the mean intra-cycle FF AMH concentrations and this variable was used as the outcome in the statistical models. Urinary concentrations of phthalate metabolites were investigated individually as well as the ∑DEHP and ∑non-DEHP, based on similar exposure sources previously found among women in the EARTH Study (Souter et al., 2020). Then, exposure variables were categorized into tertiles, with the lowest tertiles considered as the reference group. We applied cluster-weighted generalized estimating equation models (CWGEE) to evaluate the associations of tertiles of urinary phthalate metabolite concentrations with log-transformed FF AMH concentrations adjusting for potential confounders. As previously noted in an application to women in EARTH, CWGEE is predicted to provide efficient estimates in the presence of a different number of IVF cycles contributed per woman, as women with more cycles have more difficulty getting pregnant, provided that the lack of balance can be accurately predicted by all measured covariates in the adjusted model (Yland et al., 2019; Williamson et al., 2003).

To enhance the interpretation of the results, population marginal means (Searle et al., 1980) were presented adjusting for all the covariates in the model (at the mean level for continuous variables and weighted according to their relative frequencies for categorical variables). Confounding was assessed using prior knowledge on biological relevance and descriptive statistics from our study population using a directed acyclic graph (DAG) (Supplemental Fig. 1). The variables considered as potential confounders included factors previously related to female reproductive endpoints (Rooney and Domar, 2014; Sharma et al., 2013), and factors associated with urinary phthalate metabolites and reproductive outcomes, including FF AMH concentrations, in this study. In addition, we included well-known predictors in the fully adjusted models regardless of statistical significance since it has been demonstrated that this can improve the precision of the exposure estimates in the model (Schisterman et al., 2009). Final models were adjusted for urinary dilution (SG), age, race, body mass index (BMI), and stimulation protocol type. Statistical analyses were conducted with SAS (version 9.4; SAS Institute Inc., Cary, NC, USA). Statistical tests were two-tailed and all p-values < 0.05 were regarded as statistically significant.

*Environ Int. Author manuscript; available in PMC 2022 November 19.*
3. Results

The 138 women included in this analysis had a median (interquartile range [IQR]) age of 34.0 (32.0, 37.0) years and BMI of 23.1 (21.2, 26.1) kg/m$^2$, were predominantly white (83%), and 24% ever smoked (Table 1). The most common infertility diagnosis was male factor (42%). Most female participants underwent a luteal phase GnRH agonist stimulation protocol (70%) during their IVF cycles, of which over half (54%) utilized intracytoplasmic sperm injection (ICSI). Median (IQR) FF AMH concentrations were 0.61 (0.23, 1.55) ng/mL.

A total of 331 urine samples were collected from the 138 women undergoing 179 fresh IVF cycles and included in this analysis (Table 2). The detection frequencies for urinary concentrations of phthalate metabolites ranged from 75% to 100%, and were similar to those found in U.S. females from the general population (CDC, 2018). Urinary concentrations of the DEHP metabolites MEHP, MEHHP, MEOHP and MECPP were highly correlated with each other ($r = 0.80$ to $0.89$) (Supplemental Table 1). Urinary concentrations of MEP, MBP, MiBP, and MBzP were moderate-to-weakly correlated with all other phthalate DEHP and non-DEHP metabolites ($r < 0.52$). Urinary phthalate metabolites among women who provided two urine samples were moderately ($r = 0.25$ for mEHP) to highly ($r = 0.65$ for mEP) correlated. We found low-to-moderate across-women variability for the measured urinary phthalate metabolites [ICC (95% CI) ranged from 0.05 (0.01–0.32 for mEHP) to 0.44 (0.33–0.56) for MBzP].

In adjusted models, urinary MEOHP concentrations were negatively associated with FF AMH concentrations (p = 0.01, Table 3). Specifically, compared to women in the first tertile of MEOHP, women both in the second and in the third tertiles, had on average, 30% lower FF AMH. We also observed other suggestive negative dose–response between urinary MECPP, ΣDEHP as well as MBzP, and FF AMH concentrations. For example, women in the first tertile of urinary MECPP had, on average, 0.56 ng/mL of FF AMH concentrations, compared to 0.28 (p = 0.15) and 0.25 ng/mL (p = 0.09) for women in the second or third tertiles, respectively.

Although associations did not reach statistical significance, we also observed decreasing FF AMH with increasing tertiles of urinary MBP, MiBP and MEHHP concentrations. Tertiles of urinary MEHP concentrations were unrelated to FF AMH among women in our study.

4. Discussion

This study findings support prior literature demonstrating that phthalate exposure in women is associated with altered intrafollicular steroidogenesis (Hannon and Flaws, 2015) and is the first, to our knowledge, showing negative associations between select urinary phthalate metabolite concentrations and FF AMH concentrations. Among women undergoing IVF in EARTH, we have reported that FF AMH concentrations are positively associated with the probability of clinical pregnancy (Sacha et al., 2020), and also that urinary phthalate metabolite concentrations are negatively related to pregnancy outcomes, such as probability of clinical pregnancy (Hauser et al., 2016). Therefore, findings from the current study, if
replicated in longitudinal studies, could provide the basis of a potential mechanism by which phthalates may affect pregnancy outcomes in women undergoing fertility treatment. From a clinical perspective, a better understanding of the role that certain environmental exposures play in conditions such as diminished ovarian reserve may help inform management of these patients and provide opportunities for guidance on ways to reduce exposure to environmental chemicals such as phthalates.

The correlations observed in our study between urinary phthalate metabolites and FF AMH in preovulatory follicles are consistent with prior studies in both humans and animals suggesting that ovarian steroid production is susceptible to phthalate exposure in women with infertility (Hannon et al., 2015; Gupta et al., 2010; Hannon et al., 2015; Hauser et al., 2016; Du et al., 2019; Svechnikova et al., 2007). For example, DEHP-treated preovulatory follicles in rats were smaller due to smaller granulosa cell areas, and produced less estrogen, leading to a lack of LH surge and anovulation (Davis et al., 1994). We report that MEOHP in particular may affect granulosa cells in women based on the inverse association with FF AMH. Altered preovulatory sterioiogenesis may contribute to the observations by Hauser et al. in this same cohort and by Machtinger et al. of decreased total, mature, and fertilized oocytes, as well as fewer high quality embryos, with increased urinary MEOHP concentrations (Hauser et al., 2016; Machtinger et al., 2018). It remains unclear why associations differed among phthalates from the same diester, for instance for MEHP, MEOHP and MEHHP. It may relate to differences in biological activity of the metabolites or the metabolism of the diester into the monoester and oxidative metabolites.

Altered FF AMH production may shed light on the negative effects of phthalate exposure on the antral follicle pool (Hannon et al., 2015; Hannon et al., 2015; Messerlian et al., 2016). Animal studies show that low level daily exposure of female mice to DEHP leads to increased PI3K signaling, a proposed mechanism for the observed acceleration of primordial follicle recruitment (Hannon et al., 2014). Over time, accelerated recruitment could lead to a prematurely exhausted cohort of antral follicles, diminished ovarian reserve, and infertility (Hannon and Flaws, 2015; Hannon et al., 2014). AMH plays a key role in inhibiting primordial follicle recruitment, and AMH gene expression in granulosa cells is induced by Bone morphogenetic protein 15 (BMP15) and Growth differentiation factor 9 (GDF9) via both Smad2/3 and PI3K/Akt pathway signalling (Roy et al., 2018). Interestingly, DEHP has been shown to decrease gdf9 mRNA expression in female mice (Liu et al., 2018); and MEHP appears to inhibit FSH-stimulated cAMP accumulation in rat granulosa cells (Treinen et al., 1990; Davis et al., 1994). Reductions in GDF9 and cAMP could reduce AMH expression (Roy et al., 2018; Taieb et al., 2011). Thus, phthalates are likely toxic to key growth factors in granulosa cells, leading to reduced production of AMH in FF, which could promote accelerated recruitment of primordial follicles and over time gradual depletion of ovarian reserve and antral follicles pools. Within the context of an IVF cycle, this may also lead to early recruitment of a dominant follicle or a limited pool of follicles, which may ultimately reduce IVF success. Finally, dysregulated PI3K signaling may be a result of reduced AMH expression rather than a direct mechanism for accelerated primordial follicle recruitment by phthalates; this requires further investigation.
The EARTH study cohort and study design have numerous strengths. Study participants were treated at a single institution with a consistent method for FF collection following EARTH study protocols. Urine is considered the optimal matrix for assessment of biomarkers of exposure for non-persistent chemicals and so our work improves on prior literature examining the association between phthalate metabolites and hormone concentrations in FF (Du et al., 2019; Calafat et al., 2015). In our study, urine for phthalate assessment was collected at two time points during the IVF cycle, which improves the exposure assessment given the relatively short half-life of phthalates and the episodic nature of the exposures. Unless patients drastically altered their activities of daily life during their IVF cycle, urinary phthalate metabolite concentrations could adequately reflect long-term exposure. However, we are not able to confirm a causative temporal association since we do not know the extent of past cumulative phthalate exposure and its impact FF AMH.

There are several important limitations to our work. First, we assess a select group of primarily white, highly educated women with infertility, who do not reflect all women with infertility and may be more susceptible to endocrine disruption than fertile women. Studying the effects of phthalate exposure in fertile women undergoing fertility treatment (i.e. for egg freezing, egg donation, or genetic reasons) would be an interesting future study. Furthermore, because there is no clinical indication for FF collection in the general population, it is not possible to compare our findings to the general population, thus limiting the generalizability of our study. To address potential varied effects of ovarian stimulation on FF AMH, we controlled for stimulation protocol in our models. Furthermore, we were unable to assess how increased phthalate exposure impacts women with polycystic ovarian syndrome (PCOS) and diminished ovarian reserve due to low numbers of women with these diagnoses. This question could be evaluated in a larger study, as well. The cross-sectional design of this study using urine samples provided during the IVF cycle prevents establishing that exposure to phthalates occurred before changes in FF AMH, which is needed to perform a proper mediation analysis. However, results from this analysis are expected to motivate further research on the topic that should include longitudinal analyses.

Our sample size was modest, though we still observed dose–response relationships between phthalate exposure and FF AMH concentrations. Available FF volumes restricted our ability to perform more than two replicates for each FF AMH measurement; more replicates may have reduced assay variability and improved our ability to detect associations with phthalate concentrations. In addition, the women who chose to participate in the EARTH study had often previously undergone IVF, and so this cohort may be biased towards patients with a poorer prognosis compared to our total clinic population. We also included only cycles with at least two FF samples for AMH quantification and phthalates measured in urine, creating the possibility of selection bias. However, the characteristics of the women in our analysis were similar to the overall EARTH study cohort, reducing the chances of selection bias. Furthermore, we still observed inverse correlations between specific phthalate metabolites and FF AMH. Importantly, contamination of FF with blood is a limitation common to all studies analyzing components of FF obtained during oocyte retrieval. Finally, assessing other intrafollicular hormones such as estradiol and progesterone, were beyond the scope of the current work but would be interesting to measure as other markers of follicle health and ovarian aging.
5. Conclusions

In this study, we demonstrate that increased urinary concentrations of selected phthalate metabolites were associated with decreased FF AMH. These findings establish an important role for FF AMH in understanding the potential effects of phthalate exposure on ovarian physiology, reproductive potential, and IVF outcomes.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We acknowledge the entire EARTH study team as well as the MGH Fertility Center embryologists for their assistance in sample collection and processing.

Financial Support

NIH grants R01ES022955, R01ES009718, R00ES026648 and P30ES000002.

Abbreviations:

| Abbreviation | Description                             |
|--------------|-----------------------------------------|
| AMH          | Anti-Müllerian hormone                  |
| MIS          | Müllerian inhibiting substance          |
| FF           | follicular fluid                        |
| IVF          | in vitro fertilization                  |
| EARTH        | Environment and Reproductive Health    |
| DEHP         | Study di-(2-ethylhexyl) phthalate       |
| BMI          | body mass index                         |
| SART         | Society for Assisted Reproductive Technology |
| GnRH         | gonadotropin-releasing hormone          |
| hCG          | human chorionic gonadotropin            |
| ELISA        | enzyme-linked immunosorbent assay       |
| PBST         | 1% BSA/PBS and Tween 20                 |
| WHO          | World Health Organization               |
| CDC          | Center for Disease Control              |
| MEP          | monoethyl phthalate                     |
| MBP          | mono-n-butyl phthalate                  |
| MiBP         | monoisobutyl phthalate                  |

*Environ Int.* Author manuscript; available in PMC 2022 November 19.
MBzP  monobenzyl phthalate
MEHP  mono(2-ethylhexyl) phthalate
MEHHP  mono(2-ethyl-5-hydroxyhexyl) phthalate
MEOHP  mono(2-ethyl-5-oxohexyl) phthalate
MECPP  and mono(2-ethyl-5-carboxypentyl) phthalate
∑DEHP  molar sum of DEHP metabolites
SG  specific gravity
IQRs  interquartile ranges
LOD  limits of detection
SDs  standard deviations
CWGEE  cluster-weighted generalized estimating equation models
ICSI  intracytoplasmic sperm injection

References
Barr DB, Wilder LC, Caudill SP, Gonzalez AJ, Needham LL, Pirkle JL, 2005. Urinary creatinine concentrations in the U.S. population: implications for urinary biologic monitoring measurements. Environ. Health Perspect 113 (2), 192–200. 10.1289/ehp.7337. [PubMed: 15687057]
Begum TF, Gerona R, Melamed J, McGough A, Lenhart N, Wong R, Mok-Lin E, Butts CD, Feingold BJ, Romeiko XX, Fujimoto VY, Bloom MS, 2020. Sources of exposure to urinary phthalates among couples undergoing infertility treatment. Int. J. Hyg. Environ. Health 229, 113567. 10.1016/j.ijheh.2020.113567.
Begum TF, Fujimoto VY, Gerona R, McGough A, Lenhart N, Wong R, Mok-Lin E, Melamed J, Butts CD, Bloom MS, 2021. A pilot investigation of couple-level phthalates exposure and in vitro fertilization (IVF) outcomes. Reprod. Toxicol 99, 56–64. 10.1016/j.reprotox.2020.11.014. [PubMed: 33271283]
Buyuk E, Seifer DB, Younger J, Grazri RV, Lieman H, 2011. Random anti-Müllerian hormone (AMH) is a predictor of ovarian response in women with elevated baseline early follicular follicle-stimulating hormone levels. Fertil. Steril 95 (7), 2369–2372. 10.1016/j.fertnstert.2011.03.071. [PubMed: 21497340]
Calafat AM, Longnecker MP, Koch HM, Swan SH, Hauser R, Goldman LR, Lanphear BP, Rudel RA, Engel SM, Teitelbaum SL, Whyatt RM, Wolff MS, 2015. Optimal exposure biomarkers for nonpersistent chemicals in environmental epidemiology. Environ. Health Perspect 123 (7) 10.1289/ ehp.1510041.
Caudill SP, Schleicher RL, Pirkle JL, 2008. Multi-rule quality control for the age-related eye disease study. Stat. Med 27 (20), 4094–4106. [PubMed: 18344178]
CDC. 2018. Centers for Disease Control and Prevention. Fourth Report on Human Exposure to Environmental Chemicals, Updated Tables, (March 2018) Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Available at https://www.cdc.gov/exposurerreport/ (accessed July 2018).
Chavarro JE, Ehrlich S, Colaci DS, Wright DL, Toth TL, Petrozza JC, Hauser R, 2012. Body mass index and short-term weight change in relation to treatment outcomes in women undergoing assisted reproduction. Fertil. Steril 98 (1), 109–116. [PubMed: 22607889]
Commission Regulation (EU) 2018/2005 of 17 December 2018 amending Annex XVII to Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) as regards bis(2-ethylhexyl) phthalate (DEHP), dibutyl phthalate (DBP), benzyl butyl phthalate (BBP) and diisobutyl phthalate (DIBP). Off. J. Eur. Union L 322/14.

Craig ZR, Singh J, Gupta RK, Flaws JA, 2014. Co-treatment of mouse antral follicles with 17\(^{\beta}\)-estradiol interferes with mono-2-ethylhexyl phthalate (MEHP)-induced atresia and altered apoptosis gene expression. Reprod. Toxicol 45, 45–51. 10.1016/j.reprotox.2014.01.002. [PubMed: 24412242]

Davis BJ, Weaver R, Gaines LJ, Heindel JJ, 1994. Mono-(2-ethylhexyl) phthalate suppresses estradiol production independent of FSH-cAMP stimulation in rat granulosa cells. Toxicol. Appl. Pharmacol 128 (2), 224–228. [PubMed: 7940537]

Davis BJ, Maronpot RR, Heindel JJ, 1994. Di-(2-ethylhexyl) phthalate suppresses estradiol and ovulation in cycling rats. Toxicol. Appl. Pharmacol 128 (2), 216–223. [PubMed: 7940536]

Du Y, Guo N, Wang Y, Teng X, Hua X, Deng T, Yao Y, Yuan X, Li Y, 2019. Follicular fluid concentrations of phthalate metabolites are associated with altered intrafollicular reproductive hormones in women undergoing in vitro fertilization. Fertil. Steril 111 (5), 953–961. 10.1016/j.fertnstert.2019.01.021. [PubMed: 30879714]

Fanchin R, Mendez Lozano DH, Frydman N, Gougeon A, di Clemente N, Frydman R, Taieb J, 2007. Anti-Mullerian hormone concentrations in the follicular fluid of the preovulatory follicle are predictive of the implantation potential of the ensuing embryo obtained by in vitro fertilization. J. Clin. Endocrinol. Metabolism 92 (5), 1796–1802. Epub 2007/03/01. doi: 10.1210/jc.2006-1053. PubMed PMID: 17327387.

Ferguson JM, Pepin D, Duru C, Matejtschuk P, Donohoe PK, Burns CJ, 2018. Towards international standardization of immunoassays for Mullerian inhibiting substance/anti-Mullerian hormone. Reproductive Biomed. Online 37 (5), 631–640. Epub 2018/09/23. doi: 10.1016/j.rbmo.2018.08.012. PubMed PMID: 30241771.

Gaskins AJ, Fong KC, Abu Awad Y, Di Q, Miguez-Alarcon L, Chavarro JE, Ford JB, Coull BA, Schwartz J, Kلوگ Naak I, Souter I, Hauser R, Laden F, 2019. Time-Varying exposure to air pollution and outcomes of in vitro fertilization among couples from a fertility clinic. Environ. Health Perspect 127 (7), 77002. 10.1289/EHP4601. PubMed PMID: 31268361.

Green MP, Harvey AJ, Finger BJ, Tarulli GA, 2021. Endocrine disrupting chemicals: Impacts on human fertility and fecundity during the peri-conception period. Environ. Res 194, 110694. 10.1016/j.envres.2020.110694.

Gupta RK, Singh JM, Leslie TC, Meachum S, Flaws JA, Yao HHC, 2010. Di-(2-ethylhexyl) phthalate and mono-(2-ethylhexyl) phthalate inhibit growth and reduce estradiol levels of antral follicles in vitro. Toxicol. Appl. Pharmacol 242 (2), 224–230. 10.1016/j.taap.2009.10.011. [PubMed: 19874833]

Hannon PR, Peretz J, Flaws JA, 2014. Daily Exposure to Di(2-ethylhexyl) Phthalate Alters Estrous Cyclicity and Accelerates Primordial Follicle Recruitment Potentially Via Dysregulation of the Phosphatidylinositol 3-Kinase Signaling Pathway in Adult Mice1. Biol. Reprod 90 (6) 10.1095/biolreprod.114.119032.

Hannon PR, Bannick KE, Wang W, Flaws JA, 2015. Mono(2-Ethylhexyl), phthalate accelerates early folliculogenesis and inhibits steroidogenesis in cultured mouse whole ovaries and antral follicles. Biol. Reprod 92 (5) 10.1095/biolreprod.115.129148.

Hannon PR, Flaws JA, 2015. The effects of phthalates on the ovary. Front. Endocrinol 6 10.3389/fendo.2015.00008.

Hannon PR, Bannick KE, Wang W, Gupta RK, Flaws JA, 2015. Di(2-ethylhexyl) phthalate inhibits antral follicle growth, induces atresia, and inhibits steroid hormone production in cultured mouse antral follicles. Toxicol. Appl. Pharmacol 284 (1), 42–53. 10.1016/j.taap.2015.02.010. [PubMed: 25701202]

Hauser R, Calafat A, 2005. Phthalates and human health. Occup. Environ. Med 62 (11), 806–818. 10.1136/oem.2004.017590. [PubMed: 16234408]

Hauser R, Gaskins AJ, Souter I, Smith KW, Dodge LE, Ehrlich S, Meeker JD, Calafat AM, Williams PL, 2016. Urinary phthalate metabolite concentrations and reproductive outcomes among women

Environ Int. Author manuscript; available in PMC 2022 November 19.
undergoing in vitro fertilization: results from the EARTH Study. Environ. Health Perspect 124 (6), 831–839. 10.1289/ehp.1509760. [PubMed: 26545148]

Heindel JJ, Blumberg B, Cave M, Machtinger R, Mantovani A, Mendez MA, Nadal A, Palanza P, Panzica G, Sargis R, Vandenberg LN, vom Saal F, 2017. Metabolism disrupting chemicals and metabolic disorders. Reprod. Toxicol 68, 3–33. 10.1016/j.reprotox.2016.10.001. [PubMed: 27760374]

Hudson PL, Dougas I, Donahoe PK, Cate RL, Epstein J, Pepinsky RB, MacLaughlin DT, 1990. An immunoassay to detect human müllerian inhibiting substance in males and females during normal development. J. Clin. Endocrinol. Metabolism 70 (1), 16–22.

Kano M, Sosulski AE, Zhang L, Saatcioglu HD, Wang D, Nagykery N, Sabatini ME, Gao G, Donahoe PK, Pepin D, 2017. AMH/MIS as a contraceptive that protects the ovarian reserve during chemotherapy. Proc. Nat. Acad. Sci. USA 114 (9), E1688–E1697. Epub 2017/02/01. doi: 10.1073/pnas.1620729114. PubMed PMID: 28137855; PubMed Central PMCID: PMC5338508. [PubMed: 28137855]

Katsikantami I, Sifakis S, Tzatzarakis MN, Vakonaki E, Kalantzi O-I, Tsatsakis AM, Rizos AK, 2016. A global assessment of phthalates burden and related links to health effects. Environ. Int 97, 212–236. [PubMed: 27669632]

Kim JH, Lee JR, Chang HJ, Jee BC, Suh CS, Kim SH, 2014. Anti-Mullerian hormone levels in the follicular fluid of the preovulatory follicle: a predictor for oocyte fertilization and quality of embryo. J. Korean Med. Sci 29 (9), 1266–1270. 10.3346/jkms.2014.29.9.1266. PubMed PMID: 25246746; PubMed Central PMCID: PMCPMC4168181. [PubMed: 25246746]

Liu J, Wang W, Zhu J, Li Y, Luo L, Huang Y, Zhang W, 2018. Di(2-ethylhexyl) phthalate (DEHP) influences follicular development in mice between the weaning period and maturity by interfering with ovarian development factors and microRNAs. Environ. Toxicol 33 (5), 535–544. 10.1002/tox.v33.510.1002/tox.22540. [PubMed: 29385306]

Machtinger R, Gaskins AJ, Racowsky C, Mansur A, Adir M, Baccarelli AA, Calafat AM, Hauser R, 2018. Urinary concentrations of biomarkers of phthalates and phthalate alternatives and IVF outcomes. Environ. Int 111, 23–31. 10.1016/j.envint.2017.11.011. [PubMed: 29161633]

Messerlian C, Souter I, Gaskins AJ, Williams PL, Ford JB, Chiu Y-H, Calafat AM, Hauser R, 2016. Urinary phthalate metabolites and ovarian reserve among women seeking infertility care. Hum. Reprod 31 (1), 75–83. 10.1093/humrep/dev292. [PubMed: 26573529]

Messerlian C, Williams PL, Ford JB, Chavarro JE, Mínguez-Alarcón L, Dadd R, Braun JM, Gaskins AJ, Meeker JD, James-Todd T, Chiu YH, Nassan FL, Souter I, Petrozza J, Keller M, Toth TL, Calafat AM, Hauser R, Team ES, 2018. The Environment and Reproductive Health (EARTH) Study: a prospective preconception cohort. Hum. Reprod. Open 2018 (2) 10.1093/hro/roy001. PubMed PMID: 29888733; PubMed Central PMCID: PMCPMC5990043.

Mínguez-Alarcón L, Gaskins AJ, Chiu Y-H, Souter I, Williams PL, Calafat AM, Hauser R, Chavarro JE, 2016. Dietary folate intake and modification of the association of urinary bisphenol A concentrations with in vitro fertilization outcomes among women from a fertility clinic. Reprod. Toxicol 65, 104–112. 10.1016/j.reprotox.2016.07.012. [PubMed: 27423903]

Mínguez-Alarcón L, Messerlian C, Bellavia A, Gaskins AJ, Chiu Y-H, Ford JB, Azevedo AR, Petrozza JC, Calafat AM, Hauser R, Williams PL, 2019. Urinary concentrations of bisphenol A, parabens and phthalate metabolite mixtures in relation to reproductive success among women undergoing in vitro fertilization. Environ. Int 126, 355–362. 10.1016/j.envint.2019.02.025. [PubMed: 30826614]

Pepin D, Hoang M, Nicolalou F, Hendren K, Benedict LA, Al-Moujahed A, Sosulski A, Marmalidou A, Vavvas D, Donahoe PK, 2013. An albumin leader sequence coupled with a cleavage site modification enhances the yield of recombinant C-terminal Mullerian Inhibiting Substance. Technology 1 (1), 63–71. Epub 2014/04/15. doi: 10.1142/S2339547813500076. PubMed PMID: 24729676; PubMed Central PMCID: PMC3980489. [PubMed: 24729676]

Rooney KL, Domar AD, 2014. The impact of lifestyle behaviors on infertility treatment outcome. Curr. Opin. Obstet. Gynecol 26 (3), 181–185. [PubMed: 24752004]

Roy S, Gandra D, Seger C, Biswas A, Kushnir VA, Gleicher N, Kumar TR, Sen A, 2018. Oocyte-derived factors (GDF9 and BMP15) and FSH regulate AMH expression via modulation of H3K27AC in granulosa cells. Endocrinology 159 (9), 3433–3445. 10.1210/en.2018-00609. [PubMed: 30060157]
Sacha CR, Harris AL, James K, Basnet K, Freret TS, Yeh J, Kaimal A, Souter I, Roberts DJ, 2019. Placental pathology in live births conceived with in vitro fertilization after fresh and frozen embryo transfer. Am. J. Obstet. Gynecol Epub Oct 4.

Sacha CR, Chavarro JE, Williams PL, Ford J, Zhang L, Donahoe PK, Souter IC, Hauser R, Pépin D, Mínguez-Alarcón L, 2020. Follicular fluid anti-Müllerian hormone (AMH) concentrations and outcomes of in vitro fertilization cycles with fresh embryo transfer among women at a fertility center. J. Assist. Reprod. Genet 37 (11), 2757–2766. 10.1007/s10815-020-01956-7. [PubMed: 33025399]

SART, 2015. Preliminary sart clinic summary report.

Schisterman EF, Whitcomb BW, Buck Louis GM, Louis TA, 2005. Lipid adjustment in the analysis of environmental contaminants and human health risks. Environ. Health Perspect 113 (7), 853–857. 10.1289/ehp.7640. [PubMed: 16002372]

Schisterman EF, Cole SR, Platt RW, 2009. Overadjustment bias and unnecessary adjustment in epidemiologic studies. Epidemiology 20 (4), 488–495. 10.1097/EDE.0b013e3181a819a1. [PubMed: 19525685]

Searle SR, Speed FM, Milliken GA, 1980. Population marginal means in the linear model: an alternative to least squares means. Am. Stat 34 (4), 216–221.

Sharma R, Biedenham KR, Fedor JM, Agarwal A, 2013. Lifestyle factors and reproductive health: taking control of your fertility. Reprod Biol. Endocrinol 11 (66), 1–15. [PubMed: 23302328]

Silva MJ, Barr DB, Reedy JA, Malek NA, Hodge CC, Caudill SP, Brock JW, Needham LL, Calafat AM, 2004. Urinary levels of seven phthalate metabolites in the U.S. population from the National Health and Nutrition Examination Survey (NHANES) 1999–2000. Environ. Health Perspect 112 (3), 331–338. 10.1289/ehp.6723. [PubMed: 14998749]

Silva MJ, Samandar E, Preau JL Jr., Reedy JA, Needham LL, Calafat AM, 2007. Quantification of 22 phthalate metabolites in human urine. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci 860 (1), 106–112. Epub 2007/11/13. doi: 10.1016/j.jchromb.2007.10.023. PubMed PMID: 17997365.

Souter I, Smith KW, Dimitriadis I, Ehrlich S, Williams PL, Calafat AM, Hauser R, 2013. The association of bisphenol-A urinary concentrations with antral follicle counts and other measures of ovarian reserve in women undergoing infertility treatments. Reprod. Toxicol 42, 224–231. 10.1016/j.reprotox.2013.09.008. PubMed PMID: 24100206; PubMed Central PMCID: PMCPMC4383527. [PubMed: 24100206]

Souter I, Bellavia A, Williams PL, Korevaar TIM, Meeker JD, Braun JM, de Poortere RA, Broeren MA, Ford JB, Calafat AM, Chavarro JE, Hauser R, Mínguez-Alarcón L, 2020. Urinary concentrations of phthalate metabolite mixtures in relation to serum biomarkers of thyroid function and autoimmunity among women from a fertility center. Environ. Health Perspect 128 (6), 067007. 10.1289/EHP6740.

Svechnikova I, Svechnikov K, Söder O, 2007. The influence of di-(2-ethylhexyl) phthalate on steroidogenesis by the ovarian granulosa cells of immature female rats. J. Endocrinol 194 (3), 603–609. 10.1677/joe-07-0238. [PubMed: 17761899]

Taieb J, Grynhberg M, Pierre A, Arouche N, Massart P, Belville C, Hesters L, Frydman R, Catteau-Jonard S, Fanchin R, Picard J-Y, Josso N, Rey RA, di Clemente N, 2011. FSH and its second messenger cAMP stimulate the transcription of human anti-Müllerian hormone in cultured granulosa cells. Mol. Endocrinol 25 (4), 645–655. 10.1210/me.2010-0297. [PubMed: 21330407]

Treinen KA, Dodson WC, Heindel JJ, 1990. Inhibition of FSH-stimulated cAMP accumulation and progesterone production by mono(2-ethylhexyl) phthalate in rat granulosa cell cultures. Toxicol. Appl. Pharmacol 106 (2), 334–340. [PubMed: 2175055]

Wang W, Craig ZR, Basavarajappa MS, Gupta RK, Flaws JA, 2012. Di (2-ethylhexyl) phthalate inhibits growth of mouse ovarian antral follicles through an oxidative stress pathway. Toxicol. Appl. Pharmacol 258 (2), 288–295. 10.1016/j.taap.2011.11.008. [PubMed: 22155089]

Weenen C, 2004. Anti-Mullerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol. Hum. Reprod 10 (2), 77–83. 10.1093/molehr/gah015. [PubMed: 14742691]

Williamson JM, Datta S, Satten GA, 2003. Marginal analyses of clustered data when cluster size is informative. Biometrics 59, 36–42. [PubMed: 12762439]
Yland J, Messerlian C, Mínguez-Alarcón L, Ford JB, Hauser R, Williams PL, 2019. Methodological approaches to analyzing IVF data with multiple cycles. Hum. Reprod 34 (3), 549–557. 10.1093/humrep/dey374. [PubMed: 30576499]
Table 1

Demographic and reproductive characteristics [median (IQR) or N (%)] among 138 women undergoing 179 IVF cycles in the Environment and Reproductive Health (EARTH) Study.

| Per woman                        |        |
|----------------------------------|--------|
| Age, years                       | 34.0 (32.0, 37.0) |
| Race, N (%)                      |        |
| White                            | 114 (83) |
| Black                            | 4 (3)   |
| Asian                            | 14 (10) |
| Other                            | 6 (4)   |
| Body Mass Index, kg/m²           | 23.1 (21.2, 26.1) |
| Ever smoked, N (%)               | 33 (24) |
| Education, N (%)                 |        |
| High school/some college         | 11 (8)  |
| College graduate                 | 40 (29) |
| Graduate degree                  | 87 (63) |
| Per cycle Infertility diagnosis, n (%) |        |
| Male factor                      | 76 (42) |
| Female factor                    | 53 (30) |
| Diminished Ovarian Reserve       | 11 (6)  |
| Endometriosis                    | 8 (4)   |
| Ovulatory Disorders              | 19 (11) |
| Tubal                            | 14 (8)  |
| Uterine                          | 1 (1)   |
| Idiopathic                       | 50 (28) |
| Treatment protocol, n (%)        |        |
| Antagonist                       | 25 (14) |
| Flare                            | 28 (16) |
| Luteal phase agonist             | 126 (70) |
| Estradiol Trigger Levels, pmol/L | 2026 (1542, 2614) |
| ICSI cycles, n (%)               | 97 (54) |
| Day 3 FSH Levels, IU/L           | 6.5 (5.8, 7.8) |
| FF AMH concentrations, ng/mL     | 0.61 (0.23, 1.55) |

*a Intracytoplasmic sperm injection

*b Follicular stimulating hormone

*c Follicular fluid

*d Anti-Müllerian hormone
Table 2

Distribution of urinary concentrations (μg/L) of phthalate metabolites among 138 women contributing 331 urine samples in the EARTH Study.

| Metabolite                                      | Detection Frequency | %     | GM (SD)          | 10th   | 25th   | 50th   | 75th   | 95th   |
|-------------------------------------------------|---------------------|-------|------------------|--------|--------|--------|--------|--------|
| Mono-n-butyl phthalate (MBP)                    | 98                  | 100   | 10.1 (0.73)      | 1.70   | 4.80   | 11.9   | 25.4   | 66.1   |
| Mono-isobutyl phthalate (MiBP)                  | 99                  | 100   | 7.87 (0.54)      | 1.60   | 3.40   | 9.50   | 18.9   | 47.4   |
| Monoethyl phthalate (MEP)                       | 100                 | 100   | 38.6 (3.11)      | 6.60   | 14.5   | 33.1   | 98.3   | 477    |
| Monobenzyl phthalate (MBzP)                     | 95                  | 100   | 3.50 (0.28)      | 0.50   | 1.22   | 3.20   | 8.70   | 34.2   |
| Mono-2-ethylhexyl phthalate (MEHP)              | 75                  | 100   | 1.70 (0.12)      | 0.35   | 0.35   | 1.60   | 3.60   | 20.6   |
| Mono-2-ethyl-5-hydroxyhexyl phthalate (MEHHP)   | 100                 | 100   | 9.11 (0.62)      | 1.90   | 3.90   | 8.70   | 19.7   | 78.8   |
| Mono-2-ethyl-5-oxohexyl phthalate (MEOHP)       | 100                 | 100   | 6.49 (0.43)      | 1.30   | 3.00   | 6.70   | 13.5   | 47.7   |
| Mono-2-ethyl-5-carboxypentyl phthalate (MECPP)  | 100                 | 100   | 16.0 (0.97)      | 3.90   | 7.20   | 16.0   | 30.5   | 116    |

Per IVF cycle (N total = 179), 1 (N = 27, 15%) or 2 (N = 152, 85%) urine samples (N = 331 total) were collected.

$^a$ Limits of detection (LOD) ranged from 0.1 to 1.2 ng/ml.
Table 3

Adjusted (adjusted mean, 95% CI) FF AMH concentrations by tertiles of urinary phthalate metabolite concentrations among 138 women undergoing 179 IVF cycles in the EARTH Study.

| Range, ng/mL | FF AMH levels, ng/mL | Range, ng/mL | FF AMH levels, ng/mL |
|--------------|----------------------|--------------|----------------------|
|              | Adjusted for Specific gravity (SG) Adjusted for SG, age, BMI, race and protocol. |              | Adjusted for SG Adjusted for SG, age, BMI, race and protocol. |
| mEHP         |                      | mBP          |                      |
| T1 (0.35–0.90) | 0.34 (0.17, 0.69)  | 0.32 (0.16, 0.63) | 0.43 (0.20, 0.90)  | 0.42 (0.20, 0.88) |
| T2 (0.94–2.34) | 0.46 (0.23, 0.92)  | 0.46 (0.23, 0.90) | T2 (6.30–16.6)  | 0.31 (0.16, 0.62)  | 0.33 (0.17, 0.64) |
| T3 (2.40–102)  | 0.27 (0.14, 0.54)  | 0.28 (0.14, 0.56) | T3 (16.7–215)  | 0.32 (0.15, 0.67)  | 0.29 (0.14, 0.60) |
| T2-T3 (0.94–102) | 0.35 (0.21, 0.58) | 0.36 (0.22, 0.59) | T2-T3 (6.30–215) | 0.32 (0.19, 0.52)  | 0.31 (0.19, 0.51) |
| mEHHP        |                      | mBP          |                      |
| T1 (0.56–5.92) | 0.44 (0.22, 0.90)  | 0.41 (0.21, 0.83) | T1 (0.14–5.13)  | 0.47 (0.22, 0.99)  | 0.46 (0.22, 0.95) |
| T2 (6.01–13.9) | 0.37 (0.19, 0.75)  | 0.36 (0.18, 0.72) | T2 (5.16–13.1)  | 0.35 (0.17, 0.70)  | 0.37 (0.19, 0.73) |
| T3 (14.0–317)  | 0.25 (0.12, 0.51)  | 0.27 (0.13, 0.54) | T3 (13.2–86.6) | 0.26 (0.12, 0.53)  | 0.23 (0.11, 0.47) |
| T2-T3 (6.01–317) | 0.31 (0.19, 0.51) | 0.31 (0.19, 0.51) | T2-T3 (5.16–86.6) | 0.30 (0.18, 0.50)  | 0.30 (0.18, 0.49) |
| mEOHP        |                      | mBP          |                      |
| T1 (0.30–4.04) | 0.77 (0.38, 1.56)  | 0.72 (0.36, 1.44) | T1 (0.80–19.0)  | 0.56 (0.28, 1.11)  | 0.53 (0.27, 1.05) |
| T2 (4.13–9.81) | 0.24 (0.12, 0.47)  | 0.23 (0.12, 0.45) | T2 (19.3–63.1)  | 0.22 (0.11, 0.44)  | 0.22 (0.11, 0.43) |
| T3 (9.90–255)  | 0.23 (0.11, 0.47)  | 0.24 (0.12, 0.48) | T3 (65.2–2610) | 0.34 (0.17, 0.68)  | 0.35 (0.18, 0.68) |
| T2-T3 (4.13–253) | 0.23 (0.14, 0.38) | 0.23 (0.14, 0.38) | T2-T3 (19.3–2610) | 0.28 (0.17, 0.45)  | 0.28 (0.17, 0.44) |
| mECP        |                      | mBP          |                      |
| T1 (1.51–10.3) | 0.58 (0.28, 1.18)  | 0.56 (0.28, 1.13) | T1 (0.21–1.77)  | 0.61 (0.30, 1.24)  | 0.57 (0.28, 1.15) |
| T2 (10.4–23.0) | 0.30 (0.15, 0.58)  | 0.28 (0.15, 0.55) | T2 (1.78–5.88)  | 0.28 (0.14, 0.57)  | 0.28 (0.14, 0.56) |
| T3 (23.1–338)  | 0.24 (0.12, 0.50)  | 0.25 (0.12, 0.51) | T3 (6.00–136)  | 0.24 (0.12, 0.49)  | 0.24 (0.12, 0.50) |
| T2-T3 (10.4–338) | 0.27 (0.16, 0.44) | 0.27 (0.16, 0.43) | T2-T3 (1.78–136) | 0.26 (0.16, 0.43)  | 0.26 (0.16, 0.43) |
| ∑DEHP       |                      | ∑DEHP         |                      |
| T1 (0.01–0.07) | 0.54 (0.27, 1.10)  | 0.50 (0.25, 1.01) | T1 (0.01–0.19)  | 0.62 (0.31, 1.24)  | 0.58 (0.29, 1.15) |
| T2 (0.08–0.16) | 0.25 (0.12, 0.49)  | 0.24 (0.12, 0.48) | T2 (0.20–0.54)  | 0.19 (0.10, 0.39)  | 0.20 (0.10, 0.39) |
| T3 (0.17–3.34) | 0.32 (0.15, 0.65)  | 0.33 (0.16, 0.68) | T3 (0.55–13.8) | 0.35 (0.18, 0.69)  | 0.35 (0.18, 0.68) |
| Range, ng/mL | FF AMH levels, ng/mL | FF AMH levels, ng/mL |
|-------------|-----------------------|-----------------------|
|             | Adjusted for Specific gravity (SG) | Adjusted for SG, age, BMI, race and protocol. | Adjusted for SG | Adjusted for SG, age, BMI, race and protocol. |
| T2-T3 (0.08–3.34) | 0.28 (0.217 0.46) ‡ | 0.28 (0.17, 0.46) ‡ | T2-T3 (0.20–13.8) | 0.26 (0.16, 0.43) ‡ | 0.26 (0.16, 0.43) ‡ |

* p-value < 0.05 when comparing that tertile/group with the lowest tertile/group.

‡ p-value < 0.10 when comparing that tertile/group with the lowest tertile/group.